Arena Pharmaceuticals downgraded by Credit Suisse with a new price target
$ARNA
Biotechnology: Pharmaceutical Preparations
Health Care
Credit Suisse downgraded Arena Pharmaceuticals from Outperform to Neutral and set a new price target of $100.00 from $98.00 previously